News & Media
|Hemostemix to Present at the 2015 Annual Meeting of the Clinical Trials Association in Israel|
|Apr 20 2015 -
Hemostemix Inc. (the “Corporation”) (TSX-V: “HEM”), a clinical-stage autologous cell-therapy company, announced today that its President and CEO, Dr. Elmar Burchardt, will present on clinical-trial strategies for critical limb ischemia (CLI) at the Annual Meeting of the Clinical Trials Association in Israel on April 28, 2015, at the David Intercontinental Hotel in Tel Aviv.
Dr. Burchardt’s presentation from 3:40-4:00 p.m. (IDT) is entitled “Autologous Cell Therapy, Clinical Development of an Autologous Cell Therapy for Critical Limb Ischemia: Building on Past Successes and Lessons Learned.”
Hemostemix is the first clinical-stage biotech company to test a potential breakthrough stem-cell therapy in an international, multicenter, phase-2 clinical trial for patients with CLI, a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. About half of CLI patients either die or require amputation of the affected limb within one year of diagnosis. Demand for a treatment is on the rise, as CLI predominately affects the growing population aged 50 and older.
The phase-2 trial targets a participant’s diseased tissue with proprietary cells that are grown from his or her blood and capable of supporting the formation of new blood vessels. Hemostemix currently enrolls participants in the phase-2 trial at four sites in South Africa and two sites in Canada.
Hemostemix operates a research, development, and manufacturing facility in Kiryat Weizmann Science Park, Ness Ziona, Israel.
For more information, please contact email@example.com